Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001214532 | SCV001386216 | uncertain significance | not provided | 2022-10-05 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 2617 of the CDH23 protein (p.Gly2617Arg). This variant is present in population databases (rs369379727, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with CDH23-related conditions. ClinVar contains an entry for this variant (Variation ID: 944185). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CDH23 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV001580572 | SCV001810321 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 12 | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001580571 | SCV001810322 | uncertain significance | Usher syndrome type 1D | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002484170 | SCV002787737 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 12; Usher syndrome type 1D; Pituitary adenoma 5, multiple types | 2021-09-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002561847 | SCV003753615 | uncertain significance | Inborn genetic diseases | 2021-09-16 | criteria provided, single submitter | clinical testing | The c.7849G>C (p.G2617R) alteration is located in exon 55 (coding exon 54) of the CDH23 gene. This alteration results from a G to C substitution at nucleotide position 7849, causing the glycine (G) at amino acid position 2617 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV001214532 | SCV005190826 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Clinical Genetics Laboratory, |
RCV001214532 | SCV005197421 | uncertain significance | not provided | 2022-05-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001214532 | SCV005328321 | uncertain significance | not provided | 2024-02-28 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Natera, |
RCV001828709 | SCV002088740 | uncertain significance | Usher syndrome type 1 | 2020-01-18 | no assertion criteria provided | clinical testing |